GlobeNewswire

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

Share

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia

GENEVA, Switzerland and BOSTONJuly2, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF2α) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.

Presentation detailsare as follows:

Title: A Randomized, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for the Treatment of Spontaneous Preterm Labor (PROLONG)

Abstract ID: W-063

Poster Session: Clinical Perinatology

Presenter: Elizabeth Garner, M.D., M.P.H., Chief Medical Officer of ObsEva

Session Date: Wednesday, July 7, 2021

Session Time: 4:00-5:30 p.m. ET

Title: Pharmaceutical Industry Development in Preterm Labor Treatment: Current Landscape

Mini Symposia II: Update on Diagnostics and Therapeutics for Preterm Birth

Presenter: Elizabeth Garner, M.D., M.D.H., Chief Medical Officer of ObsEva

Session Date: Thursday, July 8, 2021

Session Time: 5:35-6:00 p.m. ET

The link to the session will be available under “Events Calendar” in the Investors section of ObsEva’s website at www.ObsEva.com

About Ebopiprant and PGF

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Correction: AB Klaipėdos nafta financial information reporting dates in 202129.7.2021 10:15:00 CEST | Press release

Correction: AB Klaipedos nafta interim financial information for the 6 months of 2021 has been released on 29 July 2021. AB Klaipėdos nafta (further – KN) informs that it plans to release financial information in 2021 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2021KN preliminary revenues for the previous month29 January 2021Interim financial information for the year 20207 April 2021Audited financial statements for the year 202030 April 2021Interim financial information for the 1st quarter of 20218 June 2021Social responsibility report for the year 202029 July 2021Interim financial information for the 6 months of 202129 October 2021Interim financial information for the 3 quarters of 2021 On 30 April 2021, the Company plans to convene an Ordinary General Meeting of Shareholders. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276.

Hexagon Digital Wave signs new equipment and service agreement with Linde29.7.2021 09:00:00 CEST | Press release

Hexagon Digital Wave, a business of Hexagon Composites has signed an agreement with Linde, a leading industrial gas and engineering company. The agreement covers the supply and service of Ultrasonic Examination (UE) testing equipment. The estimated total value of the agreement is USD 2 million (approx. NOK 17 million) and designates Hexagon Digital Wave as a long-term partner. Driving energy transformation “We are excited to extend our relationship with the great team at Linde”, says Keith Fountain, UE international Sales Manager Hexagon Digital Wave. “Over the past 14 years we have provided our equipment to one of the market leaders in the industrial gas environment and helped to improve the safety of their cylinders.” About the market The non-destructive UE test and process enables the recertification of the cylinders without removing the internal product which improves the safety and allows a number of ESG requirements to be accomplished. Positive environmental impacts are accomplis

Nexstim Receives an NBS System Order from a University Hospital in Germany29.7.2021 09:00:00 CEST | Press release

Press release, Helsinki, 29 July 2021 at 10 AM(EEST) Nexstim Receives an NBS System Order froma University Hospital in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS System order in Germany. The customer is a German university hospital and a new customer for Nexstim. Nexstim NBS systems with SmartFocus® nTMS technology are mainly used for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumor’s or other lesion’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. Mikko Karvinen, CEO of Nexstim commented: “We are very happy about our continued success in expanding our NBS presence within the German university hospitals. This sale is a good start t

GeoJunxion NV (ticker: GOJXN.AS) Formerly called AND International Publishers NV (AND.AS) Publishes its July 2021 Trading Update29.7.2021 08:30:00 CEST | Press release

Capelle aan den Ijssel, The Netherlands 29 July 2021 - GeoJunxion significantly increases order intake and shows encouraging Q2 and 1H2021 YoY topline growth. Looking back at the first half of 2021 and more specifically at the second quarter, Covid-19 and its related measures are still proving to be a significant challenge for the global economy. However, the GeoJunxion team and our underlying business continued to show strong resilience and improved performance during Q2: Revenue during the past quarter has grown by 30% compared to the same quarter in 2020. For the first half of 2021, revenue increased by 20% compared to the same period last year. Thanks to an extraordinary Q2 performance, our order intake for the first half of 2021 doubled compared to the same period last year. We are continuously encouraged by the market response regarding our new premium location aware products and intelligence location services, which have resulted in the increased strength of our pipeline. It is

AB Klaipėdos nafta holds a Webinar regarding unaudited financial results for the six months of 202129.7.2021 08:00:00 CEST | Press release

On the 29th of July 2021 at 9:00 (EET) AB Klaipėdos nafta (hereinafter – the Company) holds a conference webinar for its shareholders, investors, mass media representatives and other stakeholders. The presentation is held in English. The webinar is hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who introduces the Company’s financial results for the six months of 2021 and will answer the participant questions. Webinar presentation is enclosed. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2

AB Klaipėdos nafta unaudited financial information regarding the six months of 202129.7.2021 07:55:00 CEST | Press release

AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the six months ended 30 June 2021. Main financial indicators of the Group comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021 Change, compared to 6 months of 2020Revenue31.6 million EUR- 22.4%31.6 million EUR- 22.4%Net profit (loss)- 6.8 million EUR- 16.2 million EUR- 0.2 million EUR- 7.5 million EUREBITDA14.6 million EUR- 39.7%14.6 million EUR- 39.7% Main financial indicators of the Company comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021Change, compared to 6 months of 2020Revenue30.1 million EUR- 24.2%30.1 million EUR- 24.2%Net profit (loss)- 7.2 million EUR- 16.5 million EUR-0.7 million EUR- 7.9 million EUR EBITDA14.0 million EUR- 41.7%14.0 mi

NOMINATION OF CHIEF FINANCIAL OFFICER29.7.2021 07:30:00 CEST | Press release

NOMINATION OF CHIEF FINANCIAL OFFICER Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces that the Supervisory Board has nominated Mike Kuehnel for appointment as Chief Financial Officer and member of the Management Board. Given Flow Traders’ ambitions and strategic growth agenda, the Supervisory Board has taken the decision to expand the Management Board from four to five members with the nomination of Mike Kuehnel for appointment as Chief Financial Officer. Through this new, dedicated Chief Financial Officer function, Mike will help to further shape Flow Traders’ strategy, develop organic and non-organic growth initiatives as well as intensify communications with key stakeholders. Mike Kuehnel will join Flow Traders on 1 August 2021 and all regulatory approvals have been received. Prior to joining Flow Traders, Mike gained over 20 years of investment banking and strategy consulting experience in the global financial market infrastructure space. Most recently, Mi